- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00561366
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2b double-blind, randomized, placebo-controlled parallel-group study evaluating the safety and efficacy of arimoclomol (400 mg t.i.d.) compared to placebo. A safety lead-in phase will be employed to ensure the safety of all study volunteers.
Tier I (Safety Lead-in): During the enrollment period for the safety lead-in phase, 24 volunteers meeting inclusion/exclusion criteria will be randomized at 4 investigative sites. These volunteers will have weekly visits during the first 4 weeks after starting treatment. Pharmacokinetics (PK) will be performed at various timepoints throughout these 4 weeks. After the initial 4 weeks of treatment, visits will continue at 4-week intervals up to Week 36, subsequently visits will occur every 8 weeks up to Week 68. A final visit will occur at Week 72. There will be a 28-day post study medication Follow-Up Telephone Call to assess medical status and adverse events.
Tier II: After the Tier I volunteers finish 4 weeks of treatment, their data will be reviewed by the IDMC and, if no serious safety issues are identified, the recommendation will be made to start the second enrollment period (Tier II). During Tier II enrollment, volunteers recruited from approximately 30 to 40 centers in the US and Canada will be randomized. After screening and randomization, volunteers will be followed every 4 weeks for 9 months. Subsequently visits will occur every 8 weeks up to Week 68, with interim Follow-Up Telephone Calls at Weeks 16, 24, and 32 and a final visit at Week 72. A Week 76 Follow-Up Telephone Call to assess medical status and adverse events will occur at 28 days post last dose of study medication.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 2G9
- University of British Columbia, Gordon and Leslie Diamond Health Care Centre - Tier 2 Site
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Science Center - Tier 2 Site
-
Toronto, Ontario, Canada, M4N 3M5
- University of Toronto, Sunnybrook Health Sciences Centre - Tier 2 Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 2B4
- Montreal Neurological Institute - Tier 2
-
-
-
-
California
-
Pacific Palisades, California, United States, 90272
- University of California Los Angeles - Tier 2 Site
-
San Francisco, California, United States, 94117
- University of California - San Francisco - Tier 2 Site
-
-
Colorado
-
Denver, Colorado, United States, 80262
- University of Colorado Health Sciences Center - Tier 2 Site
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami - Tier 2 Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University - Tier 2 site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University, Dept. of Neurology - Tier 2 Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center - Tier 2 site
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- John Hopkins University - Tier 2 Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital - Tier 1 Site
-
Springfield, Massachusetts, United States, 01199
- Baystate Medical Center - Tier 2 Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University, Neuromuscular Div. - Tier 2 Site
-
St. Louis, Missouri, United States, 63110
- Washington University - Tier 2 Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- BryanLGH Medical Center - Tier 2 Site
-
-
New York
-
Albany, New York, United States, 12205
- Upstate Clinical Research, LLC - Tier 2 Site
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine - Tier 2 Site
-
New York, New York, United States, 10032
- Columbia University Medical Center - Tier 2 site
-
Syracuse, New York, United States, 13210
- SUNY Downstate Medical Center - Tier 1 Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center - Tier 1 Site
-
Winston Salem, North Carolina, United States, 27157
- Wake Forest University School of Medicine -Tier 2 Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation -Tier 2 site
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence ALS Center - Tier 2 Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Pennsylvania State University School of Medicine - Tier 2 Site
-
Philadelphia, Pennsylvania, United States, 19107
- Drexel University College of Medicine - Tier 1 Site
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center - Tier 2 Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-2551
- Vanderbilt University Medical Center - Tier 2
-
-
Texas
-
Dallas, Texas, United States, 75214
- Texas Neurology, PA - Tier 2 Site
-
San Antonio, Texas, United States, 78229-3900
- University of Texas Health Science Center - Tier 2 Site
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- University of Vermont, College of Medicine - Tier 2
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia - Tier 2 Sites
-
-
Washington
-
Seattle, Washington, United States, 98101
- Virginia Mason Clinic - Tier 2 Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin - Tier 2 Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Familial or sporadic ALS.
- Diagnosed with laboratory-supported probable, probable or definite ALS according to the World Federation of Neurology El Escorial criteria for less than or equal to 36 months' duration prior to the Screening Visit.
- Vital capacity (VC) equal to or greater than 70% predicted value for gender, height and age at the Screening Visit.
- Geographic accessibility to the study site.
- Ability to take oral medication at the Screening Visit, based on verbal report.
- Fluency in English, Spanish or Canadian French.
Exclusion Criteria:
- History of known sensitivity or intolerability to arimoclomol or to any other related compound.
- Prior exposure to arimoclomol through a clinical trial or physician-sponsored IND.
- Exposure to any investigational agent within 30 days of the Screening Visit.
Presence of any of the following clinical conditions:
- Substance abuse within the past year
- Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease
- AIDS or AIDS-related complex
- Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression within 90 days of the Screening Visit.
- Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, creatinine clearance less than 70 cc/min, alanine aminotransferase (ALT) greater than 3.0 times the upper limit of normal, total bilirubin greater than 1.5 times the upper limit of normal, white blood cell (WBC) count less than 3,500/mm3, platelet concentration of <100,000/ul, hematocrit level of less than 33 % for female or less than 35 % for male, or coagulation tests (PT, PTT) greater than or equal to 1.5 times upper limit of normal.
- Female volunteers who are breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2
|
capsule, 400 mg t.i.d.
|
Placebo Comparator: 1
|
Placebo t.i.d.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ALSFRS-R
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ALSFRS-R
Time Frame: 18 months
|
18 months
|
Survival
Time Frame: 18 months
|
18 months
|
Muscle strength
Time Frame: 9 and 18 months
|
9 and 18 months
|
Pulmonary function
Time Frame: 9 and 18 months
|
9 and 18 months
|
MUNE
Time Frame: 9 and 18 months
|
9 and 18 months
|
Quality of Life
Time Frame: 9 and 18 months
|
9 and 18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeremy Shefner, MD, PhD, State University of New York - Upstate Medical University
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AALS-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States